Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Investigator Sponsored Studies

    Investigator Sponsored Studies supports independent researchers and their institutions with clinical, observational, and nonclinical research to advance knowledge of serious diseases and improve patient care.

    OverviewSimilar Grants
    OverviewSimilar Grants

    This grant was recently updated

    Beta thalassemia and sickle cell disease submissions moved from a closed RFP cycle to rolling acceptance, with concept and protocol decisions expected within 45 days. Vertex added interest in innovative real-world effectiveness and safety studies and is not prioritizing prospective studies using G-CSF as a mobilization agent.

    Investigator-Initiated Studies

    Investigator-Initiated Studies supports physicians and researchers conducting studies of AbbVie products and therapeutic interests to expand scientific knowledge and inform patient care.

    AbbVieRolling submissions

    Investigator Initiated Studies

    Investigator Initiated Studies support independent investigators and institutions conducting clinical and basic science research to advance knowledge of CSL products and the diseases they treat.

    CSL BehringDue Nov 20, 2026

    Investigator-Initiated Studies

    Investigator-Initiated Studies supports independent researchers through Sarepta Therapeutics funding or study materials to answer medical and scientific questions in rare neuromuscular diseases.

    SareptaRolling submissions

    Investigator Sponsored Studies - Amgen

    Investigator Sponsored Studies - Amgen supports external sponsors conducting clinical research on Amgen products or diseases of interest to advance science, clinical medicine, and patient care.

    AmgenRolling submissions

    Investigator Sponsored Studies and Externally Sponsored Collaboration

    Investigator Sponsored Studies and Externally Sponsored Collaboration supports external researchers and institutions studying topics aligned with Ipsen’s interests to advance medical knowledge.

    IpsenDue Feb 11, 2027